A carregar...
Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
Eliglustat is a first‐line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6‐metabolizer phenotypes (90% of patients). We report real‐world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Regis...
Na minha lista:
| Publicado no: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7497238/ https://ncbi.nlm.nih.gov/pubmed/32438452 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25875 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|